Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Case Description
3.1.1. Case 1
3.1.2. Case 2
3.1.3. Case 3
3.1.4. Case 4
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Grever, M.R.; Abdel-Wahab, O.; Andritsos, L.A.; Banerji, V.; Barrientos, J.; Blachly, J.S.; Call, T.G.; Catovsky, D.; Dearden, C.; Demeter, J.; et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017, 129, 553–560. [Google Scholar] [CrossRef] [Green Version]
- Robak, T.; Matutes, E.; Catovsky, D.; Zinzani, P.L.; Buske, C. ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015, 26, v100–v107. [Google Scholar] [CrossRef]
- Smith, A.; Howell, D.; Patmore, R.; Jack, A.S.; Roman, E.P. Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. Br. J. Cancer 2011, 105, 1684–1692. [Google Scholar] [CrossRef] [Green Version]
- Teras, L.R.; DeSantis, C.E.; Cerhan, J.R.; Morton, L.M.; Jemal, A.; Flowers, C.R. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA A Cancer J. Clin. 2016, 66, 443–459. [Google Scholar] [CrossRef]
- Tiacci, E.; Trifonov, V.; Schiavoni, G.; Holmes, A.; Kern, W.; Martelli, M.P.; Pucciarini, A.; Bigerna, B.; Pacini, R.; Wells, V.A.; et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 2011, 364, 2305–2315. [Google Scholar] [CrossRef] [Green Version]
- Flinn, I.W.; Kopecky, K.J.; Foucar, M.K.; Head, D.; Bennett, J.M.; Hutchison, R.; Corbett, W.; Cassileth, P.; Habermann, T.; Golomb, H.; et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000, 96, 2981–2986. [Google Scholar]
- Goodman, G.R.; Burian, C.; Koziol, J.A.; Saven, A. Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine. J. Clin. Oncol. 2003, 21, 891–896. [Google Scholar] [CrossRef] [PubMed]
- Zinzani, P.L.; Pellegrini, C.; Stefoni, V.; Derenzini, E.; Gandolfi, L.; Broccoli, A.; Argnani, L.; Quirini, F.; Pileri, S.; Baccarani, M. Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients. Cancer 2010, 116, 4788–4792. [Google Scholar] [CrossRef]
- Else, M.; Dearden, C.E.; Matutes, E.; Garcia-Talavera, J.; Rohatiner, A.Z.S.; Johnson, S.A.N.; O’Connor, N.T.J.; Haynes, A.; Osuji, N.; Forconi, F.; et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br. J. Haematol. 2009, 145, 733–740. [Google Scholar] [CrossRef]
- Kreitman, R.J.; Tallman, M.S.; Robak, T.; Coutre, S.; Wilson, W.H.; Stetler-Stevenson, M.; Fitzgerald, D.J.; Lechleider, R.; Pastan, I. Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients with Hairy Cell Leukemia. J. Clin. Oncol. 2012, 30, 1822–1828. [Google Scholar] [CrossRef]
- Kreitman, R.J.; Dearden, C.; Zinzani, P.L.; Delgado, J.; Karlin, L.; Robak, T.; Gladstone, D.E.; Le Coutre, P.; Dietrich, S.; Gotic, M.; et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 2018, 32, 1768–1777. [Google Scholar] [CrossRef]
- Kreitman, R.J.; Dearden, C.; Zinzani, P.L.; Delgado, J.; Robak, T.; le Coutre, P.D.; Gjertsen, B.T.; Troussard, X.; Roboz, G.J.; Karlin, L.; et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): Long-term follow-up from the pivotal trial. J. Hematol. Oncol. 2021, 14, 1–11. [Google Scholar] [CrossRef]
- Tiacci, E.; Park, J.H.; De Carolis, L.; Chung, S.S.; Broccoli, A.; Scott, S.; Zaja, F.; Devlin, S.; Pulsoni, A.; Chung, Y.R.; et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N. Engl. J. Med. 2015, 373, 1733–1747. [Google Scholar] [CrossRef] [PubMed]
- Dietrich, S.; Pircher, A.; Endris, V.; Peyrade, F.; Wendtner, C.-M.; Follows, G.A.; Hüllein, J.; Jethwa, A.; Ellert, E.; Walther, T.; et al. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood 2016, 127, 2847–2855. [Google Scholar] [CrossRef] [Green Version]
- Liebers, N.; Roider, T.; Bohn, J.-P.; Haberbosch, I.; Pircher, A.; Ferstl, B.; Ebnöther, M.; Wendtner, C.-M.; Dearden, C.; Follows, G.A.; et al. BRAF inhibitor treatment in classic hairy cell leukemia: A long-term follow-up study of patients treated outside clinical trials. Leukemia 2019, 34, 1454–1457. [Google Scholar] [CrossRef] [PubMed]
- Kreitman, R.J.; Moreau, P.; Hutchings, M.; Gazzah, A.; Blay, J.-Y.; Wainberg, Z.A.; Stein, A.; Dietrich, S.; De Jonge, M.J.; Willenbacher, W.; et al. Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). Blood 2018, 132, 391. [Google Scholar] [CrossRef]
- Tiacci, E.; De Carolis, L.; Simonetti, E.; Capponi, M.; Ambrosetti, A.; Lucia, E.; Antolino, A.; Pulsoni, A.; Ferrari, S.; Zinzani, P.L.; et al. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N. Engl. J. Med. 2021, 384, 1810–1823. [Google Scholar] [CrossRef] [PubMed]
- Tiacci, E.; Schiavoni, G.; Forconi, F.; Santi, A.; Trentin, L.; Ambrosett, A.; Cecchini, D.; Sozzi, E.; Francia di Celle, P.; Di Bello, C.; et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 2012, 119, 192–195. [Google Scholar] [CrossRef] [Green Version]
- Troussard, X.; Grever, M.R. The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant. Br. J. Haematol. 2021, 193, 11–14. [Google Scholar] [CrossRef]
- Assanto, G.M.; Riemma, C.; Malaspina, F.; Perrone, S.; De Luca, M.L.; Pucciarini, A.; Annechini, G.; D’Elia, G.M.; Martelli, M.; Foà, R.; et al. The current role of interferon in hairy cell leukaemia: Clinical and molecular aspects. Br. J. Haematol. 2021. [Google Scholar] [CrossRef]
- Habermann, T.M.; Rai, K. Historical treatments of in hairy cell leukemia, splenectomy and interferon: Past and current uses. Leuk. Lymphoma 2011, 52, 18–20. [Google Scholar] [CrossRef]
- Kreitman, R.J.; Tallman, M.S.; Robak, T.; Coutre, S.; Wilson, W.H.; Stetler-Stevenson, M.; Fitzgerald, D.J.; Santiago, L.; Gao, G.; Lanasa, M.C.; et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: Phase 1 results and long-term follow-up. Blood 2018, 131, 2331–2334. [Google Scholar] [CrossRef] [PubMed]
- Janus, A.; Robak, T. Moxetumomab pasudotox for the treatment of hairy cell leukemia. Expert Opin. Biol. Ther. 2019, 19, 501–508. [Google Scholar] [CrossRef] [PubMed]
- Tiacci, E.; De Carolis, L.; Simonetti, E.; Merluzzi, M.; Bennati, A.; Perriello, V.M.; Pucciarini, A.; Santi, A.; Venanzi, A.; Pettirossi, V.; et al. Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: A pilot phase-2 clinical trial. Leukemia 2021. [Google Scholar] [CrossRef]
- Rogers, K.A.; Andritsos, L.A.; Wei, L.; McLaughlin, E.; Ruppert, A.S.; Anghelina, M.; Blachly, J.S.; Call, T.G.; Chihara, D.; Dauki, A.M.; et al. Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia. Blood 2021. [Google Scholar] [CrossRef]
- Shenoi, D.P.; Andritsos, L.A.; Blachly, J.S.; Rogers, K.A.; Moran, M.E.; Anghelina, M.; Jones, J.A.; Grever, M.R. Classic hairy cell leukemia complicated by pancytopenia and severe infection: A report of 3 cases treated with vemurafenib. Blood Adv. 2019, 3, 116–118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bohn, J.P.; Pircher, A.; Wanner, D.; Vill, D.; Foeger, B.; Wolf, D.; Steurer, M. Low-dose vemurafenib in hairy cell leukemia patients with active infection. Am. J. Hematol. 2019, 94, E180–E182. [Google Scholar] [CrossRef] [Green Version]
- Robak, E.; Jesionek-Kupnicka, D.; Iskierka-Jazdzewska, E.; Janus, A.; Robak, T. Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab. Leuk. Res. 2021, 104, 106571. [Google Scholar] [CrossRef]
- Moore, J.E.; Delibert, K.; Baran, A.M.; Evans, A.G.; Liesveld, J.L.; Zent, C.S. Targeted therapy for treatment of patients with classical hairy cell leukemia. Leuk. Res. 2021, 102, 106522. [Google Scholar] [CrossRef]
- Smirnova, S.Y.; Al-Radi, L.S.; Moiseeva, T.N.; Gemdzhian, E.G.; Yakutik, I.A.; Julhakyan, H.L.; Novikov, V.A.; Galstyan, G.M.; Sudarikov, A.B. Inhibitor of BRAFV600E Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications. Clin. Lymphoma Myeloma Leuk. 2021. [Google Scholar] [CrossRef]
- Burotto, M.; Stetler-Stevenson, M.; Arons, E.; Zhou, H.; Wilson, W.; Kreitman, R.J. Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia. Clin. Cancer Res. 2013, 19, 6313–6321. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Age at Diagnosis/Sex | Therapies Before Moxe * | Moxe Treatment * | Vem + R Treatment | Response to V + R * | Subsequent Treatment * | |
---|---|---|---|---|---|---|
1 | 28/F | 1. 2-CdA (PR; 21 m) | 40 µg/kg iv × 3 every 28 days × 6 (PR; 22 m) | Vem 240 mg BID for 16 weeks + R 375 mg/m2/d/iv/every 2 weeks × 8 | MRD negative CR (ongoing at 38 m) | None |
2. 2-CdA + R (PR; 6 m) | ||||||
3. IFN-α (PR; 17 m) | ||||||
4. 2-CdA (PR; 26 m) | ||||||
2 | 33/F | 1. 2-CdA × 2 courses (PR; 15 m) | 40 µg/kg iv × 3 every 28 days × 6 (PR; 11 m) | Vem 960 mg BID for 2 weeks, (intolerance), dose reduction to 240 mg BID for 14 weeks + R 375 mg/m2/d/iv/every 2 weeks × 8 | Hematologic response (18 m) | Vem 240 mg BID for 16 weeks + R 375 mg/m2/d/iv/every 2 weeks × 8 (MRD positive CR; 17 m). Dabrafenib (75–150 mg/d BID po) + trametinib 2 mg/day indefinitely (ongoing hematologic remission; 2 m) |
2. IFN-α (NR) | ||||||
3. 2-CdA + R (PR; 6 m) | ||||||
3 | 53/M | 1. 2-CdA (CR; 18 m) | 40 µg/kg iv × 3 every 28 d × 6 (CR MRD-; 17 m) | Vem 240 mg BID for 16 weeks + R 375 mg/m2/d/iv/every 2 weeks × 8 | MRD negative CR (13 m) | Vem 240 mg BID for 7 weeks + R 375 mg/m2/d/iv/4 doses; Splenectomy (PR; 5 m) |
2. 2-CdA (CR; 27 m) | Vem 240 mg BID for 16 weeks + R 375 mg/m2/d/iv/every two weeks × 8 (hematologic remission; 4 m) | |||||
3. 2-CdA (CR; 98 m) | Dabrafenib (75–150 mg/d BID po) + trametinib 2 mg/day indefinitely (hematologic remission; 10 m) | |||||
4 | 45/M | 1. 2-CdA (PR; 22 m) | 40 µg/kg IV × 3 every 28 d × 6 (CR MRD+; 38 m) | Vem 960 mg BID for three weeks, Only 1 dose of R due to infection | Not evaluable | Died after three weeks of treatment with vemurafenib due to pneumonia and septic shock |
2. 2-CdA (PR; 27 m) | ||||||
3. 2-CdA (CR; 144 m) | ||||||
4. 2-CdA (PR; 23 m) | ||||||
5. 2-CdA (PR; 16 m) | ||||||
6. 2-CdA + R (PR; 24 m) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Robak, T.; Janus, A.; Jamroziak, K.; Tiacci, E.; Kreitman, R.J. Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. J. Clin. Med. 2021, 10, 2800. https://doi.org/10.3390/jcm10132800
Robak T, Janus A, Jamroziak K, Tiacci E, Kreitman RJ. Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. Journal of Clinical Medicine. 2021; 10(13):2800. https://doi.org/10.3390/jcm10132800
Chicago/Turabian StyleRobak, Tadeusz, Agnieszka Janus, Krzysztof Jamroziak, Enrico Tiacci, and Robert J. Kreitman. 2021. "Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox" Journal of Clinical Medicine 10, no. 13: 2800. https://doi.org/10.3390/jcm10132800
APA StyleRobak, T., Janus, A., Jamroziak, K., Tiacci, E., & Kreitman, R. J. (2021). Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. Journal of Clinical Medicine, 10(13), 2800. https://doi.org/10.3390/jcm10132800